{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:59:14Z","timestamp":1760403554972,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["N01MH90001"],"award-info":[{"award-number":["N01MH90001"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/TA\/002\/2012"],"award-info":[{"award-number":["NMRC\/TA\/002\/2012"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009048","name":"Japanese Society of Clinical Neuropsychopharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001350","name":"Ministry of Health -Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007263","name":"Astellas Foundation for Research on Metabolic Disorders","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010523","name":"Centre for Addiction and Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010523","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.euroneuro.2014.12.008","type":"journal-article","created":{"date-parts":[[2015,1,9]],"date-time":"2015-01-09T12:19:40Z","timestamp":1420805980000},"page":"295-302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8844-4786","authenticated-orcid":false,"given":"Hiroyoshi","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gagan","family":"Fervaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimmy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofer","family":"Agid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2014.12.008_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.12.008_bib2","first-page":"32","article-title":"Once daily risperidone in treatment of schizophrenia","volume":"43","author":"Agarwal","year":"2001","journal-title":"Indian J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.008_bib3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1176\/ps.49.8.1095","article-title":"Patients\u2019 preferences about medication dosing regimens","volume":"49","author":"Balon","year":"1998","journal-title":"Psychiatry Serv."},{"key":"10.1016\/j.euroneuro.2014.12.008_bib4","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.008_bib5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/070674370304800307","article-title":"A random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study","volume":"48","author":"Chengappa","year":"2003","journal-title":"Can. J. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.euroneuro.2014.12.008_bib6","first-page":"9","article-title":"What are we looking for in new antipsychotics?","volume":"72","author":"Correll","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.008_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0924-9338(11)71709-6","article-title":"Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups","volume":"26","author":"Correll","year":"2011","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.008_bib8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.clinthera.2009.03.002","article-title":"Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects","volume":"31","author":"Datto","year":"2009","journal-title":"Clin. Ther."},{"year":"1976","series-title":"ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338","author":"Guy","key":"10.1016\/j.euroneuro.2014.12.008_bib9"},{"key":"10.1016\/j.euroneuro.2014.12.008_bib10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The quality of life scale: an instrument for rating the schizophrenic deficit syndrome","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.12.008_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0033291700050182","article-title":"A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity","volume":"13","author":"Hogan","year":"1983","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2014.12.008_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-244X-12-27","article-title":"Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?","volume":"12","author":"Jauhar","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.008_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.12.008_bib14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/YIC.0b013e3282f39703","article-title":"Effects of antipsychotic medications on sleep in schizophrenia","volume":"23","author":"Krystal","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.12.008_bib15","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.euroneuro.2014.12.008_bib16","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1046\/j.1365-2125.2000.00147.x","article-title":"Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers","volume":"49","author":"Miceli","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.12.008_bib17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1600-0447.2009.01356.x","article-title":"The subjective experience of taking antipsychotic medication: a content analysis of Internet data","volume":"120","author":"Moncrieff","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2014.12.008_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00004714-199804000-00002","article-title":"Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group","volume":"18","author":"Nair","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.12.008_bib19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/FTD.0b013e3182708ec5.","article-title":"Therapeutic drug monitoring of common antipsychotics","volume":"34","author":"Patteet","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.euroneuro.2014.12.008_bib20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.mehy.2013.11.043","article-title":"Clozapine administered once versus twice daily: does it make a difference?","volume":"82","author":"Procyshyn","year":"2014","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.euroneuro.2014.12.008_bib21","unstructured":"Risperdal [package insert (revised: August 2012)]. Janssen Pharmaceuticals Inc. Available at: http:\/\/www.janssenpharmaceuticalsinc.com\/assets\/risperdal.pdf. Accessed: January 9, 2014"},{"key":"10.1016\/j.euroneuro.2014.12.008_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.euroneuro.2014.12.008_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.12.008_bib24","doi-asserted-by":"crossref","first-page":"506","DOI":"10.4088\/JCP.13m08695","article-title":"Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data","volume":"75","author":"Takeuchi","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.008_bib25","first-page":"679","article-title":"Do we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristics","volume":"6","author":"Witticke","year":"2012","journal-title":"Patient Preference Adherence"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14003551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14003551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:50:58Z","timestamp":1760377858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X14003551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0924977X14003551"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.12.008","relation":{},"ISSN":["0924-977X"],"issn-type":[{"type":"print","value":"0924-977X"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}